167993-12-6

Upstream product

• 99-31-0 5-aminoisophthalic acid 
• 13438-30-7 5-nitro-1,3-benzenedicarbonylchloride 
• 618-88-2 5-nitrobenzene-1,3-dicarboxylic acid 

Downstream Products

• 1378942-75-6 tetra-tert-butyl 5,5'-(carbonylbis(azanediyl))diisophthalate 
• 1334547-47-5 5,5′,5″-(4,4′,4″-(benzene-1,3,5-triyl)tris(1H-1,2,3-triazole-4,1-diyl))-triisophthalic acid 
• 167992-83-8 N-(9-fluorenylmethoxycarbonyl)-1S-(3,5-di-t-butyloxycarbonylphenylaminocarbonyl)-2-(4-iodophenyl)ethylamine 

Relevant academic research and scientific papers

SYNTHETIC PROCESSES AND INTERMEDIATES

The invention provides synthetic processes and synthetic intermediate compounds that can be used to prepare therapeutic conjugates. The invention also provides methods for treating HBV and/or HDV infection in a human by administering a therapeutic conjugate prepared by the synthetic methods of the invention.

COMPOUND, CURED PRODUCT, POLYMER, PHOTO-ALIGNMENT FILM, OPTICALLY ANISOTROPIC BODY AND LIQUID CRYSTAL DISPLAY ELEMENT

A compound and a polymer which can each form a photo-alignment film having excellent ability of controlling alignment, a photo-alignment film obtained using the polymer and an optically anisotropic body and a liquid crystal display element each having the photo-alignment film are provided. A compound represented by the general formula (1). In the formula, P represents a polymerizable group, Z and Z1 represent divalent linking groups, A and A1 represent divalent cyclic groups, and X1 to X5 each independently represent a hydrogen atom, a fluorine atom, a chlorine atom, a hydroxy group, a nitro group, a cyano group or an alkyl group having 1 to 40 carbon atoms which may have a substituent, provided that X1, X2, X4 and X5 are not simultaneously hydrogen atoms.

Urea metal-organic frameworks as effective and size-selective hydrogen-bond catalysts

A new urea-containing metal-organic framework (MOF) was synthesized to act as a heterogeneous catalyst. Ureas are well-known for self-recognition and aggregation behavior, resulting in loss of catalytic competency. The catalyst spatial isolation achievable in a porous MOF environment suggests a potentially general solution. The combination of a symmetrical urea tetracarboxylate strut, 4,4′-bipyridine, and Zn(NO3)2?6H2O under solvothermal conditions afforded a new microporous MOF (NU-601). This material is indeed an effective hydrogen-bond-donor catalyst for Friedel-Crafts reactions between pyrroles and nitroalkenes, whereas a homogeneous urea is much less competent. The higher rates of reaction of small substrates relative to larger ones with NU-601 strongly suggest that catalysis primarily occurs within the pores of this new material rather than on its exterior. To the best of our knowledge, this approach is the first example of specific engineering of successful hydrogen-bonding catalysis into a MOF material.

GASTIN AND CCK RECEPTOR LIGANDS

Compounds of formula (Ia), (Ib), or (Ic), wherein A represents a group having two fused rings, or a group of formula (Id), R 1 (m) represents up to 6 substituents, K represents--O--,--S--,--CH 2--,--N(R 2)--or--N(COR 2)--, in which R 2 is H or C 1 to C 3 alkyl, W is a carbonyl, sulfonyl or sulfinyl group, provided that at least one of W and X contains carbonyl, Y and Z are as given in the description, and their pharmaceutically acceptable salts are ligands at CCK and/or gastrin receptors. STR1

Catalytic antibody regulated prodrug therapy

Catalytic antibodies capable of catalysing activation of a carbamate (-O-CO-NH-) containing prodrug suitable for Antibody Directed Abzyme Prodrug Therapy (ADAPT) by catalysing breakdown of the prodrug at the carbamate position by a non-spontaneous reaction mechanism. The non-spontaneous reaction preferably has a BAc2 mechanism and the prodrug is a preferably a nitrogen mustard aryl carbamate. The invention also includes relevant immunogens, screens for catalytic activity using short transition state analogues and ADAPT systems.